Antiemetic Efficacy of Adding Olanzapine 5 mg to Aprepitant, Palonosetron and Dexamethasone-Sparing After Day Two for Cancer Patients Receiving Anthracycline and Cyclophosphamide

References

• National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Breast Cancer. Version 1; 2020 Available from: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed 121, 2020..
   Google Scholar
• Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008;26(5):778–785.18258986
   PubMed Web of Science ®Google Scholar
• Peto R, Davies C, et al.; Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012;379(9814):432–444.22152853
   PubMed Web of Science ®Google Scholar
• Fossati R, Confalonieri C, Torri V, et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol. 1998;16(10):3439–3460.9779724
   PubMed Web of Science ®Google Scholar
• Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J. Delayed nausea and vomiting continue to reduce patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol. 2006;24(27):4472–4478.16983116
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Antiemesis. Version 1. 2019; 2020 Available from: https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf. Accessed 121, 2020.
   Google Scholar
• Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2017;35(28):3240–3261.28759346
   PubMed Web of Science ®Google Scholar
• Multinational Association of Supportive Care in Cancer. MASCC/ESMO antiemetic guideline 2016 with updates in 2019; 2020 Available from: https://www.mascc.org/assets/Guidelines-Tools/mascc_antiemetic_guidelines_english_v.1.5SEPT29.2019.pdf. Accessed 310, 2020.
   Google Scholar
• Bymaster FP, Calligaro DO, Falcone JF, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 1996;14(2):87–96.8822531
   PubMed Web of Science ®Google Scholar
• Bymaster FP, et al. Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and α1-adrenergic receptors in vitro. Schizophr Res. 1999;37(1):107–122. doi:10.1016/S0920-9964(98)00146-710227113
   PubMed Web of Science ®Google Scholar
• Navari RM, Qin R, Ruddy KJ, et al. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med. 2016;375(2):134–142. doi:10.1056/NEJMoa151572527410922
   PubMed Web of Science ®Google Scholar
• Yanai T, Iwasa S, Hashimoto H, et al. A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy. Int J Clin Oncol. 2018;23(2):382–388.29039073
   PubMed Web of Science ®Google Scholar
• Ito Y, Tsuda T, Minatogawa H, et al. Placebo-controlled, double-blinded phase III study comparing dexamethasone on day 1 with dexamethasone on days 1 to 3 with combined neurokinin-1 receptor antagonist and palonosetron in high emetogenic chemotherapy. J Clin Oncol. 2018;36(10):1000–1006.29443652
   PubMed Web of Science ®Google Scholar
• Vardy J, Chiew KS, Galica J, Pond GR, Tannock IF. Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer. 2006;94(7):1011–1015.16552437
   PubMed Web of Science ®Google Scholar
• Nakamura M, Ishiguro A, Muranaka T, et al. A Prospective observational study on effect of short-term periodic steroid premedication on bone metabolism in gastrointestinal cancer. Oncologist. 2017;22(5):592–600.28341762
   PubMed Web of Science ®Google Scholar
• Waks AG, Tolaney SM, Galar A, et al. Pneumocystis jiroveci pneumonia (PCP) in patients receiving neoadjuvant and adjuvant anthracycline-based chemotherapy for breast cancer: incidence and risk factors. Breast Cancer Res Treat. 2015;154(2):359–367.26420402
   PubMed Web of Science ®Google Scholar
• Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illnesses and prior corticosteroid therapy. Mayo Clin Proc. 1996;71(1):5–13.8538233
   PubMed Web of Science ®Google Scholar
• Yeo W, Lai TK, Li L, et al. A randomized study of olanzapine-containing versus standard antiemetic regimens for the prevention of chemotherapy-induced nausea and vomiting in Chinese breast cancer patients. Breast. 2020;50:30–38.31978815
   PubMed Web of Science ®Google Scholar
• Ithimakin S, Theeratrakul P, Laocharoenkiat A, et al. Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy. Support Care Cancer. 2020;28(11):5335–5342.32128615
   PubMed Web of Science ®Google Scholar
• Kawazoe H, Uozumi R, Murakami A, et al. Olanzapine plus aprepitant, palonosetron, and dexamethasone for nausea and vomiting in patients with breast cancer receiving anthracycline: a retrospective study. Sci Rep. 2018;8(1):16232.30389996
   PubMed Web of Science ®Google Scholar
• Amamoto T, Irie S, Kumamoto M, et al. Effect of food on LU170053 (Olanzapine) bioavailability and the bioequivalence of different formulations. Rinshouiyaku. 1998;14(15):2717–2735.
   Google Scholar
• Lemos Duarte I, Da Silveira N, Lima JP, et al. Dose-dense chemotherapy versus conventional chemotherapy for early breast cancer: a systematic review with meta-analysis. Breast. 2012;21(3):343–349.22425607
   PubMed Web of Science ®Google Scholar
• Mastro LD, Placido SD, Bruzi P, et al. Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised Phase 3 trial. Lancet. 2015;385(9980):1863–1872.25740286
   PubMed Web of Science ®Google Scholar
• Saito M, Aogi K, Sekine I et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol.2009;10(2):115–124.
   Google Scholar